7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Sheng ZF et al. | Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. | 2009 | Osteoporos Int | pmid:18496637 |
Ermakov S et al. | A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma. | 2012 | Osteoporos Int | pmid:22057548 |
Xie H et al. | Omentin-1 exerts bone-sparing effect in ovariectomized mice. | 2012 | Osteoporos Int | pmid:21755404 |
Nakashima A et al. | Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. | 2011 | Osteoporos Int | pmid:20812007 |
Khosla S et al. | Correlates of osteoprotegerin levels in women and men. | 2002 | Osteoporos Int | pmid:12086350 |
D'Amelio P et al. | Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. | 2011 | Osteoporos Int | pmid:21116815 |
Pennisi P et al. | Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. | 2004 | Osteoporos Int | pmid:14661073 |
Jørgensen L et al. | Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. | 2010 | Osteoporos Int | pmid:19701599 |
Ferrari-Lacraz S and Ferrari S | Do RANKL inhibitors (denosumab) affect inflammation and immunity? | 2011 | Osteoporos Int | pmid:20571772 |
Leder BZ and Finkelstein JS | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. | 2005 | Osteoporos Int | pmid:15856361 |
Simpson CA et al. | Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. | 2014 | Osteoporos Int | pmid:24927689 |
Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
Mangiafico RA et al. | Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. | 2008 | Osteoporos Int | pmid:17676381 |
Fiore CE et al. | Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. | 2005 | Osteoporos Int | pmid:15983730 |
Maïmoun L et al. | In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels. | 2011 | Osteoporos Int | pmid:21359671 |
Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
Hamed AA and Fayad JN | Presence of otosclerosis and paget lesions in the same temporal bone. | 2009 | Otol. Neurotol. | pmid:19779387 |
Kuczkowski J et al. | [Molecular control of bone resorption in chronic otitis media with cholesteatoma]. | 2010 Jul-Aug | Otolaryngol Pol | pmid:20873097 |
Cervellati C et al. | Higher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia. | 2016 | Oxid Med Cell Longev | pmid:26635910 |
Songia P et al. | Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model. | 2017 | Oxid Med Cell Longev | pmid:28261377 |
Heitzer E et al. | IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer. | 2012 Nov-Dec | Pain Physician | pmid:23159968 |
Satoh K et al. | Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. | 2001 | Pancreas | pmid:11590320 |
Pietrapertosa AC et al. | Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. | 2009 | Panminerva Med | pmid:19352306 |
Gulseren A et al. | Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. | 2011 | Panminerva Med | pmid:21659972 |
D'Amore M et al. | Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. | 2006 | Panminerva Med | pmid:17215793 |
Michou L et al. | [Molecular analysis of Paget's disease of bone]. | 2007 Apr-May | Pathol. Biol. | pmid:16884862 |
Ikeda T et al. | Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. | 2003 | Pathol. Int. | pmid:12828610 |
Quan J et al. | Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. | 2012 | Pathology | pmid:22406484 |
Won KY et al. | RANK signalling in bone lesions with osteoclast-like giant cells. | 2011 | Pathology | pmid:21532526 |
Levidou G et al. | TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. | 2013 | Pathology | pmid:23277172 |
Chan MH et al. | Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. | 2005 | Pathology | pmid:15875734 |
Ishii R et al. | High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. | 2006 | Pediatr Blood Cancer | pmid:16358318 |
Skordis N et al. | Hormonal dysregulation and bones in thalassaemia--an overview. | 2008 | Pediatr Endocrinol Rev | pmid:19337163 |
Angelopoulos NG et al. | Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. | 2007 Oct-Nov | Pediatr Hematol Oncol | pmid:17786784 |
Rianthavorn P et al. | Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. | 2010 | Pediatr. Nephrol. | pmid:20676692 |
Wasilewska A et al. | Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. | 2010 | Pediatr. Nephrol. | pmid:20602239 |
Siomou E et al. | Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. | 2011 | Pediatr. Nephrol. | pmid:21479768 |
Ketteler M et al. | "Missing" inhibitors of calcification: general aspects and implications in renal failure. | 2005 | Pediatr. Nephrol. | pmid:15549415 |
Swolin-Eide D et al. | The novel bone alkaline phosphatase B1x isoform in children with kidney disease. | 2006 | Pediatr. Nephrol. | pmid:16932897 |
Rosso DA et al. | Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. | 2006 | Pediatr. Res. | pmid:16439593 |
Bargman R et al. | High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. | 2012 | Pediatr. Res. | pmid:22926546 |
Vidal K et al. | Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. | 2004 | Pediatr. Res. | pmid:15155868 |
Honsawek S et al. | Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. | 2009 | Pediatr. Surg. Int. | pmid:19184056 |
Petersson M et al. | Oxytocin stimulates proliferation of human osteoblast-like cells. | 2002 | Peptides | pmid:12126740 |
Bartold PM et al. | Mechanisms and control of pathologic bone loss in periodontitis. | 2010 | Periodontol. 2000 | pmid:20403105 |
Nagasawa T et al. | Roles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. | 2007 | Periodontol. 2000 | pmid:17214836 |
Wang AY | Vascular and other tissue calcification in peritoneal dialysis patients. | 2009 | Perit Dial Int | pmid:19270239 |
Nemec K and Schubert-Zsilavecz M | [Future therapies for metabolic bone diseases. New concepts and targets]. | 2001 | Pharm Unserer Zeit | pmid:11715689 |
Treuheit MJ et al. | Inverse relationship of protein concentration and aggregation. | 2002 | Pharm. Res. | pmid:12033388 |
Pipes GD et al. | Optimization and applications of CDAP labeling for the assignment of cysteines. | 2005 | Pharm. Res. | pmid:16028006 |